Lsv Asset Management Supernus Pharmaceuticals, Inc. Transaction History

Lsv Asset Management

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$34.93 - $42.03 $76,846 - $92,466	-2,200 Reduced 8.94%	22,400 $812,000
Q3 2022 Nov 07, 2022	SELL	$28.79 - $35.41 $89,249 - $109,770	-3,100 Reduced 11.19%	24,600 $833,000
Q1 2022 May 12, 2022	SELL	$28.51 - $32.9 $19,957 - $23,030	-700 Reduced 2.46%	27,700 $895,000
Q4 2021 Jan 28, 2022	SELL	$26.37 - $34.22 $232,056 - $301,136	-8,800 Reduced 23.66%	28,400 $828,000
Q3 2021 Nov 04, 2021	SELL	$23.54 - $31.39 $3.68 Million - $4.91 Million	-156,500 Reduced 80.8%	37,200 $992,000
Q2 2021 Aug 04, 2021	SELL	$26.72 - $33.19 $22.2 Million - $27.6 Million	-830,600 Reduced 81.09%	193,700 $5.96 Million
Q1 2021 Apr 30, 2021	BUY	$24.15 - $31.45 $57,960 - $75,480	2,400 Added 0.23%	1,024,300 $26.8 Million
Q4 2020 Feb 08, 2021	BUY	$17.7 - $25.81 $3.72 Million - $5.42 Million	210,100 Added 25.88%	1,021,900 $25.7 Million
Q3 2020 Oct 23, 2020	BUY	$20.2 - $25.05 $2.33 Million - $2.89 Million	115,434 Added 16.58%	811,800 $16.9 Million
Q2 2020 Aug 05, 2020	SELL	$17.09 - $24.89 $66,651 - $97,071	-3,900 Reduced 0.56%	696,366 $16.5 Million
Q1 2020 May 07, 2020	BUY	$14.45 - $24.69 $128,605 - $219,741	8,900 Added 1.29%	700,266 $12.6 Million
Q4 2019 Feb 10, 2020	BUY	$19.93 - $29.13 $405,316 - $592,416	20,337 Added 3.03%	691,366 $16.4 Million
Q3 2019 Nov 07, 2019	BUY	$25.47 - $33.37 $16.6 Million - $21.7 Million	650,329 Added 3141.69%	671,029 $18.4 Million
Q2 2019 Aug 08, 2019	BUY	$29.96 - $38.87 $620,172 - $804,609	20,700 New	20,700 $684,000

302

60.7M

22.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.73B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

Stay updated on Lsv Asset Management with notifications on news.